Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01269593 · ClinicalTrials.gov registry record · Early Phase 1
PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study
A Early Phase 1 study of Non-Hodgkin's Lymphoma and Myeloma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT01269593: Active Early Phase 1 study of Non-Hodgkin's Lymphoma and Myeloma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01269593 is a Early Phase 1 study of Non-Hodgkin's Lymphoma and Myeloma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 63 participants, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01269593, a Early Phase 1 study of Non-Hodgkin's Lymphoma and Myeloma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see how a new drug, named PUH71, accumulates in the different parts of the body \& inside tumors and how long PUH71 lasts in the blood, when given to study participants in tiny amounts. The results of this study will help researchers (1) plan how they will use PUH71 as an experimental new drug (at much-higher doses) for the treatment of cancer, in clinical trials; and (2) know whether PUH71 might be used as a drug for detecting tumors with scanner machines.
Primary Outcome
of 124I-PUH71 in patients with solid malignancy, myeloproliferative neoplasm, myeloma, and/or lymphoma.
Conditions Studied
Interventions
- DRUG PET Imaging using 124 IPUH71
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2010-12 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
What the registry record for NCT01269593 still lists
NCT01269593 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (71% lower).
The record links to 3 conditions, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which PET Imaging using 124 IPUH71 is the first listed.
NCT01269593 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01269593 about?
NCT01269593 is a clinical study titled "PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study". The purpose of this study is to see how a new drug, named PUH71, accumulates in the different parts of the body \& inside tumors and how long PUH71 lasts in the blood, when given to study participants in tiny amounts. The results of this study will help researchers (1) plan how they will use PUH71 a...
What is the current status of trial NCT01269593?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 63 participants. The study started on 2010-12. Estimated completion is 2026-12.
What conditions does trial NCT01269593 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma, Myeloma, Active Solid Malignancy.
What interventions are being tested in trial NCT01269593?
The interventions under investigation include: PET Imaging using 124 IPUH71 (DRUG).
Who is sponsoring clinical trial NCT01269593?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01269593 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01269593's enrollment target sits among peer trials
63 27th of 63 higher than 37 of 63 other Non-Hodgkin's Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin's Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
COMPLETED · Early Phase 1
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
Cord Blood Transplant in Adults With Blood Cancers
RECRUITING · Phase 2
-
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
RECRUITING
-
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia